This book reaches out to a wide variety of professionals in the biomedical field with an interest in inflammatory bowel disease (IBD). Enormous progress has been made in the last few years since the publication of the first edition in the study of complex diseases and IBD, with hundreds of genomic regions identified that are associated with increased risk. Authored by leading clinical and research scientists in the field, the book includes state-of-the art synopses of recent genetic findings, and their interpretation for current and future exploitation in translational approaches to personalized medicine in IBD. The book also covers risk prediction, improved diagnostic and therapeutic precision, dissection of disease phenotypes and subtypes, identification of biomarkers, and host gene-microbiota interactions of clinical relevance.
Table des matières
Part 1: The Foundation of IBD Genetics, Human and Animal Studies.- A Primer on IBD: Phenotypes, Diagnosis, Treatment and Clinical Challenges.- Genetic Epidemiology of Inflammatory Bowel Disease, Early Twin and Family Studies.- Insights from Recent Advances in Animal Models of Inflammatory Bowel Disease.- Part 2: The Genetic and Molecular Makeup of Inflammatory Bowel Disease.- Complex Disease Genes and their Discovery.- The Genetics of Crohn’s Disease.- Genetics of Ulcerative Colitis.- Genetic Overlap between Inflammatory Bowel Disease and Other Diseases.- Molecular Profiling of IBD Subtypes/Response to Therapy.- Epigenetics of Inflammatory Bowel Disease.- Part 3: Pathogenetic Pathways in Inflammatory Bowel Disease.- Nod1 and Nod2 and the Immune Response to Bacteria.- The IL-23-Th17 Axis in Intestinal Inflammation.- Inflammatory Bowel Disease at the Intersection of Autophagy and Immunity: Insights from Human Genetics.- The Epithelial Barrier.- Host Interactions with Bacteria: From “Entente Cordiale” to “Casus Belli”.- Cytokines in Inflammatory Bowel Disease.- Part 4: Concluding Remarks and Future Perspectives.- Towards Personalized Therapy in Inflammatory Bowel Disease.- Index.
A propos de l’auteur
Charlotte Hedin, MD Ph D
Dr Charlotte Hedin is a specialist in luminal gastroenterology at the Karolinska University Hospital in Stockholm. She completed her Ph D on Crohn’s disease pathogenesis at King’s College London and Queen Mary University of London. In 2017 she was awarded a UEG Rising Star award for her research in IBD, and in 2018 the Karolina prize for “Exemplary patient flow and quality work” at the Karolinska Hospital. She holds a clinical post-doctorate from the Karolinska Hospital. She is a member of the Swedish Organisation for the study of IBD (SOIBD)) and is committee member for the European Crohn’s and Colitis Organisation (ECCO). In addition she collaborates in international IBD research projects, (including the GEM project). Dr Hedin’s research focusses on delineating pathogenic pathways in IBD through studying at-risk individuals (families of IBD patients) and defining the process of mucosal healing.
John D. Rioux, Ph D Dr John D. Rioux is a Full Professor of Medicine at Université de Montréal (Ude M) and Senior Researcher at the Montreal Heart Institute (MHI) and holder of the Canada Research Chair in Genetics and Genomic Medicine. He is a founding member of multiple international consortia and currently co-leads the International IBD Genetics Consortium, is Chair of the Steering Committee of the NIDDK IBD Genetics Consortium and is the leader of the IBD Genomic Medicine (
i Geno Med) Consortium. Dr. Rioux’s research focuses on three main areas: (1) genetic studies to identify risk factors for common and rare diseases; (2) functional studies to understand how these genetic risk factors protect or predispose to disease; and (3) integrative human studies to identify predictive biomarkers of important clinical outcomes. Dr. Rioux’s work has led to over 200 publications, cited over 30, 000 times.
Mauro D’Amato, Ph D
Dr Mauro D’Amato is Professor of Genetics and Genomics and Head of the Gastrointestinal Genetics Unit at the School of Biological Sciences, Faculty of Science, Monash University in Melbourne, Australia. He conceived and coordinates the largest gene-mapping effort in irritable bowel syndrome, the bellygenes initiative exploiting data from >800, 000 individuals, has served in the Management Committee of several consortia including the International IBD Genetics Consortium, and is member of the European Microscopic Colitis Group. His team combine genomic, computational and pre-clinical expertise to elucidate the pathogenetic mechanisms predisposing to inflammatory and functional gastrointestinal diseases. The druggable genome, nutrigenetics and host (genome) – microbiota interactions are also new research lines within the group. D’Amato’s research has resulted in more than 150 publications and over 13, 000 citations.
Plus d’ebooks du même auteur(s) / Éditeur
45 444 Ebooks dans cette catégorie
